Delon La Puma

Especialista en Neurología en Barcelona.
Hospital Quironsalud de Barcelona/CEMCAT Vall d'Hebron

[NeurologyLive® @neurology_live]

The FDA has approved intravenous ocrelizumab for children and adolescents aged 10+ with RRMS, supported by phase 3 OPERETTA 2 data comparing the therapy with fingolimod.

📌 Pediatric MS accounts for ~3-5% of all MS cases globally
📌 Ocrelizumab demonstrated noninferiority in ARR reduction
📌 Dosing every 6 months may offer an additional management consideration for families and clinicians

Our coverage: https://t.co/7WzyZVoWcF

[Delon La Puma @drdlapuma]

https://t.co/ibufj168ey

[MSJ @MSJ_Research]

🔊 Listen to @bollo_luca @cemcat_em @UABBarcelona @AVidalJordana @neurosantpau
@ALugaresi on OCT to predict disease progression and brain and spinal atrophy in primary progressive #MultipleSclerosis.

📄And read the full manuscript ▶️ https://t.co/5hqAFM8oYX

[JAMA Neurology @JAMANeuro]

Viewpoint: The updated 2024 McDonald criteria enable MS diagnosis in asymptomatic individuals by incorporating imaging and CSF biomarkers, such as CVS and κ-FLC index, while promoting a single standardized framework. https://t.co/7xElt5zqIp

[Headache Journal @HeadacheJournal]

Open Access:
🧠 #Gepants for kids? Early real-world evidence shows these preventives were generally safe and offered some benefit for youth with #migraine. More research is needed.
Read more: https://t.co/e4YErWaYSp
@aagelfand et al

[NeurologyLive® @neurology_live]

🚨 OnabotulinumtoxinA (Botox) did not meet efficacy goals for episodic migraine, though safety remained consistent.

🧠 Findings highlight need to explore biological differences between episodic & chronic migraine to refine treatments.

🔗 ➡️ https://t.co/Gq8oiSuwhL

[MStranslate @MStranslate]

BREAKING NEWS: @Roche have announced their BTK inhibitor, #fenebrutinib, has achieved successful trial results in both relapsing-remitting & primary progressive #MultipleSclerosis. #MS [1/2]

Read more: https://t.co/r9YP533Aw7

[Xavier Montalban @XMontalban]

It has been a pleasure to host you for #ECTRIMS25.
The whole @cemcat_em team wishes you a safe trip back and a restful weekend. Looking forward to seeing you in #Toronto next year (my second favourite city!)

[Jesús Porta-Etessam @DrJesusPorta]

Migraña: el enemigo invisible que condiciona cuerpo, mente y vida - ABC - https://t.co/UP6JGOMmXJ

[IJMSC @IJMSCtweets]

MAGNIMS–CMSC–NAIMS:"...we provide practical recommendations for imaging strategies & acquisition #MRI protocols for all aspects of #MultipleSclerosis #diagnosis, including sequences for detection of optic nerve lesions and...for assessment of CVS & PRL..." https://t.co/JGoJLFuC8k

[Cemcat @cemcat_em]

Liderat pel Dr. @XMontalban i amb la participació de la Dra. @MarTintore, Dr. @J_SastreGarriga, Dra. @GeoArrambide, Dra. Susana Otero i Dr. Alex Rovira (IDI) de @cemcat_em @vallhebron @VHIR_ es publica a @TheLancetNeuro l'actualització 2024 dels criteris diagnòstics de l'#esclerosimutliple que faciliten el diagnòstic abans dels símptomes i inici de tractament per evitar l'aparició de la discapacitat a mig i llarg termini

[Xavier Montalban @XMontalban]

Thrilled to share the 2024 revisions of the diagnostic Mc Donald criteria and companion papers @ECTRIMS @mssociety @MSIntFederation @vallhebron @FundacioEM @esclerosiseme @cemcat_em @ACTRIMS @EuropeanCharcot @TheLancetNeuro @UABBarcelona @u_medicina https://t.co/wqYkfLHhBx

[Delon La Puma @drdlapuma]

https://t.co/ezugtqui0P

[Alex Jaimes @Alex__Jaimes]

Proud to share our new publication in Cephalalgia!

📄 The RESCUE study: Atogepant in migraine patients unresponsive to anti-CGRP mAbs

🎯 18% achieved ≥50% ↓ in headache days
🧠 59% reported improvement
👉 https://t.co/o1qsR4WxH0
#migraine #CGRP #neurology

[Delon La Puma @drdlapuma]

https://t.co/Ng3Qq9MPtt

[JAMA Neurology @JAMANeuro]

Author Manuel Comabella discusses Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome with JAMA Neurology Web Editor Cynthia Armand. Listen now: https://t.co/0qB8wc1wJi

[Vall d'Hebron Institut de Recerca @VHIR_]

La Dra. @ppozorosich, cap del grup de Cefalea i Dolor Neurològic del #VHIR, explica a @LaVanguardia la importància dels gepants per al tractament de la migranya: "els podem recomanar de forma preventiva".

Llegeix-ho 👇
https://t.co/bAcwcmvIhl

[Jesús Porta-Etessam @DrJesusPorta]

Migraine prevalence remains high in Spain, causing a substantial burden and representing a major public health problem.
https://t.co/zmunqI1qnO

[JAMA Neurology @JAMANeuro]

RCT: Rizatriptan provided limited benefits for headache-related symptoms but not vertigo in treating vestibular migraine attacks. https://t.co/j6om2hqCMu

[Simona Sacco @Simona_Sacco_]

Pleased to share the release of the new Migraine Guideline!

A joint effort by the @SISCCefalee and @ihs_official

Two versions are available on @JCephalalgia :
• Summary version: https://t.co/kTUXlYkPNy
• Extended version: https://t.co/P3LQGVHQ00